Close
Achema middle east
swop processing & packaging

Avid Bioservices, Argonaut Enter Manufacturing Services Pact

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

How Can Digital Tools Improve Medication Adherence in Patients?

Medication adherence has long been one of healthcare’s toughest...

Russia, Vietnam Collaborate on Biopharma Technology Transfer

Russia and Vietnam have gone on to officially formalize...

Trump Order to Go Heavy on D2C Pharmaceutical Ads

US President Donald Trump is all set to order...

Is US Planning Executive Order on Chinese Pharma Companies?

It is worth noting that the pharmaceutical sector’s recent...

Avid Bioservices, Inc., a biologics CDMO, and Argonaut Manufacturing Services, a cGMP contract manufacturing organization (CMO) have entered a co-marketing agreement to provide an integrated manufacturing solution including process development, drug substance manufacturing, and drug product manufacturing. The companies will offer Avid’s upstream and downstream process development and drug substance manufacturing services in tandem with Argonaut’s parenteral drug product fill-finish services, to support the efficient delivery of CGMP parenteral drug products for use in clinical studies.

“As we continue to expand our biologics manufacturing client base, Avid is leveraging a strategy of aligning with industry leaders that are capable of offering critical complementary services to our customers,” said Timothy Compton, chief commercial officer of Avid. “In entering this agreement with Argonaut, we are offering our clients access to CGMP qualified parenteral fill-finish services within an hour’s drive from our drug substance development and manufacturing facilities. This will provide a drug substance-to-drug product solution for our clients as they move their novel, high-value biologic therapeutics through clinical development.”

“Argonaut has always endeavored to provide our clients with a trusted network of complementary service providers through our Ecosystem Partnership program,” said Eric Blair, chief commercial officer of Argonaut. “Our partnership with Avid unlocks key process development and drug substance manufacturing capabilities for our clients, which are a perfect fit with our state-of-the-art aseptic fill-finish offering. Together, Avid and Argonaut offer a complete solution for customers that are bringing biologic therapeutics to market.”

Latest stories

Related stories

How Can Digital Tools Improve Medication Adherence in Patients?

Medication adherence has long been one of healthcare’s toughest...

Russia, Vietnam Collaborate on Biopharma Technology Transfer

Russia and Vietnam have gone on to officially formalize...

Trump Order to Go Heavy on D2C Pharmaceutical Ads

US President Donald Trump is all set to order...

Is US Planning Executive Order on Chinese Pharma Companies?

It is worth noting that the pharmaceutical sector’s recent...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »